VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | MSI in patients with stage III colon cancer receiving 5-FU with or without oxaliplatin

Romain Cohen, MD, PhD, Saint-Antoine Hospital, AP-HP, Paris, France, outlines the results of a meta-analysis of 12 adjuvant trials evaluating the efficacy of adjuvant fluoropyrimidine with or without oxaliplatin in patients with microsatellite instable (MSI) stage III colon cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter